Patrick Van Beneden

Associate Partner
Health & Care

Patrick Van Beneden joined Gimv in 1985 and has built a successful track record in life sciences, both in early and late stage investments and exits (Devgen, CropDesign, Plexxikon, Endosense,…).

He is currently representing Gimv on the boards of JenaValve, Biotalys, GTX medical and Fire1. Former board seats include Innogenetics, Crucell, Hypnion (acquired by Eli Lilly), CropDesign (acquired by BASF), Astex and Ablynx.

Patrick has a degree in financial sciences from Vlekho in Brussels.